{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T08:56:28Z","timestamp":1767171388356,"version":"build-2238731810"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,7,10]],"date-time":"2014-07-10T00:00:00Z","timestamp":1404950400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/1471-2407-14-503","type":"journal-article","created":{"date-parts":[[2014,7,9]],"date-time":"2014-07-09T21:02:14Z","timestamp":1404939734000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["BiOsimilaRs in the management of anaemia secondary to chemotherapy in HaEmatology and Oncology: results of the ORHEO observational study"],"prefix":"10.1186","volume":"14","author":[{"name":"The ORHEO study group","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauricette","family":"Michallet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Luporsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Soubeyran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia Ali","family":"Amar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Boulanger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Carreiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louis-Marie","family":"Dourthe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Luc","family":"Labourey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Lepille","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Maloisel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Loup","family":"Mouysset","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Nahon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00e9reng\u00e8re","family":"Narciso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Nouyrigat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raouf","family":"Radji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nac\u00e9ra","family":"Sakek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9l\u00e8ne","family":"Albrand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,7,10]]},"reference":[{"key":"4717_CR1","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1016\/j.ejca.2004.06.019","volume":"40","author":"H Ludwig","year":"2004","unstructured":"Ludwig H, Van Belle S, Barrett-Lee P, Birgeg\u00e5rd G, Bokemeyer C, Gasc\u00f3n P, Kosmidis P, Krzakowski M, Nortier J, Olmi P, Schneider M, Schrijvers D: The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer. 2004, 40: 2293-2306.","journal-title":"Eur J Cancer"},{"key":"4717_CR2","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1093\/annonc\/mdh235","volume":"15","author":"D Cella","year":"2004","unstructured":"Cella D, Kallich J, McDermott A, Xu X: The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials. Ann Oncol. 2004, 15: 979-986.","journal-title":"Ann Oncol"},{"key":"4717_CR3","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1002\/1097-0142(20010615)91:12<2214::AID-CNCR1251>3.0.CO;2-P","volume":"91","author":"JJ Caro","year":"2001","unstructured":"Caro JJ, Salas M, Ward A, Goss G: Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer. 2001, 91: 2214-2221.","journal-title":"Cancer"},{"issue":"Suppl 3","key":"4717_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1634\/theoncologist.13-S3-1","volume":"13","author":"MS Aapro","year":"2008","unstructured":"Aapro MS: Anemia management with erythropoiesis-stimulating agents: a risk-benefit update. Oncologist. 2008, 13 (Suppl 3): 1-3.","journal-title":"Oncologist"},{"issue":"Suppl 8","key":"4717_CR5","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1053\/sonc.2002.33533","volume":"29","author":"H Ludwig","year":"2002","unstructured":"Ludwig H: Anemia of hematologic malignancies: what are the treatment options?. Semin Oncol. 2002, 29 (Suppl 8): 45-54.","journal-title":"Semin Oncol"},{"key":"4717_CR6","doi-asserted-by":"crossref","first-page":"702","DOI":"10.5858\/2007-131-702-CROTAA","volume":"131","author":"SL Stramer","year":"2007","unstructured":"Stramer SL: Current risks of transfusion-transmitted agents: a review. Arch Pat Lab Med. 2007, 131: 702-707.","journal-title":"Arch Pat Lab Med"},{"key":"4717_CR7","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.jamcollsurg.2008.11.019","volume":"208","author":"AC Bernard","year":"2009","unstructured":"Bernard AC, Davenport DL, Chang PK, Vaughan TB, Zwischenberger JB: Intraoperative transfusion of 1 U to 2 U packed red blood cells is associated with increased 30-day mortality, surgical-site infection, pneumonia, and sepsis in general surgery patients. J Am Coll Surg. 2009, 208: 931-937.","journal-title":"J Am Coll Surg"},{"key":"4717_CR8","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1016\/j.athoracsur.2005.12.037","volume":"81","author":"CG Koch","year":"2006","unstructured":"Koch CG, Li L, Duncan AI, Mihaljevic T, Loop FD, Starr NJ, Blackstone EH: Transfusion in coronary artery bypass grafting is associated with reduced long-term survival. Ann Thorac Surg. 2006, 81: 1650-1657.","journal-title":"Ann Thorac Surg"},{"key":"4717_CR9","doi-asserted-by":"publisher","first-page":"200","DOI":"10.2215\/CJN.03840907","volume":"3","author":"IC Macdougall","year":"2008","unstructured":"Macdougall IC: Novel erythropoiesis-stimulating agents: a new era in anemia management. Clin J Am Soc Nephrol. 2008, 3: 200-207.","journal-title":"Clin J Am Soc Nephrol"},{"key":"4717_CR10","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1517\/14656566.9.5.839","volume":"9","author":"JM Topf","year":"2008","unstructured":"Topf JM: CERA: third-generation erythropoiesis-stimulating agent. Expert Opin Pharmacother. 2008, 9: 839-849.","journal-title":"Expert Opin Pharmacother"},{"key":"4717_CR11","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1517\/14712590802652280","volume":"9","author":"I Wauters","year":"2009","unstructured":"Wauters I, Vansteenkiste J: Darbepoetin alfa in the treatment of chemotherapy-induced anaemia. Expert Opin Biol Ther. 2009, 9: 221-230.","journal-title":"Expert Opin Biol Ther"},{"key":"4717_CR12","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1159\/000318897","volume":"125","author":"J Bohlius","year":"2011","unstructured":"Bohlius J, Tonia T, Schwarzer G: Twist and shout: one decade of meta-analyses of erythropoiesis-stimulating agents in cancer patients. Acta Haematol. 2011, 125: 55-67.","journal-title":"Acta Haematol"},{"key":"4717_CR13","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1016\/S0140-6736(09)60502-X","volume":"373","author":"J Bohlius","year":"2009","unstructured":"Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, Zwahlen M, Clarke M, Weingart O, Kluge S, Piper M, Rades D, Steensma DP, Djulbegovic B, Fey MF, Ray-Coquard I, Machtay M, Moebus V, Thomas G, Untch M, Schumacher M, Egger M, Engert A: Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet. 2009, 373: 1532-1542.","journal-title":"Lancet"},{"key":"4717_CR14","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1007\/s11095-010-0288-2","volume":"28","author":"V Brinks","year":"2011","unstructured":"Brinks V, Hawe A, Basmeleh AH, Joachin-Rodriguez L, Haselberg R, Somsen GW, Jiskoot W, Schellekens H: Quality of original and biosimilar epoetin products. Pharm Res. 2011, 28: 386-393.","journal-title":"Pharm Res"},{"key":"4717_CR15","volume-title":"Biosimilars Handbook","author":"European Generic Medicines Association","year":"2011","unstructured":"European Generic Medicines Association: Biosimilars Handbook. 2011, London: Sage Publications Ltd, 2","edition":"2"},{"key":"4717_CR16","unstructured":"CHMP: Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003920.pdf ,"},{"key":"4717_CR17","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1093\/jnci\/91.19.1616","volume":"91","author":"JE Groopman","year":"1999","unstructured":"Groopman JE, Itri LM: Chemotherapy-induced anemia in adults: incidence and treatment. J Nat Cancer Inst. 1999, 91: 1616-1634.","journal-title":"J Nat Cancer Inst"},{"key":"4717_CR18","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982, 5: 649-655.","journal-title":"Am J Clin Oncol"},{"key":"4717_CR19","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1177\/1758834012444499","volume":"4","author":"M Aapro","year":"2012","unstructured":"Aapro M, Cornes P, Sun D, Abraham I: Comparative cost efficiency across the European G5 countries of originators and a biosimilar erythropoiesis-stimulating agent to manage chemotherapy-induced anemia in patients with cancer. Ther Adv Med Oncol. 2012, 4: 95-105.","journal-title":"Ther Adv Med Oncol"},{"key":"4717_CR20","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1185\/03007990903050876","volume":"25","author":"V Tzekova","year":"2009","unstructured":"Tzekova V, Mihaylov G, Elezovic I, Koytchev R: Therapeutic effects of epoetin zeta in the treatment of chemotherapy-induced anaemia. Curr Med Res Opin. 2009, 25: 1689-1697.","journal-title":"Curr Med Res Opin"},{"key":"4717_CR21","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1046\/j.1365-2141.2001.02715.x","volume":"113","author":"F Dammacco","year":"2001","unstructured":"Dammacco F, Castoldi G, R\u00f6djer S: Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma. Br J Haematol. 2001, 113: 172-179.","journal-title":"Br J Haematol"},{"key":"4717_CR22","first-page":"348","volume-title":"Hematology Am Soc Hematol Educ Program","author":"JA Zonder","year":"2006","unstructured":"Zonder JA: Thrombotic complications of myeloma therapy. Hematology Am Soc Hematol Educ Program. 2006, 348-355."},{"key":"4717_CR23","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1111\/j.1600-0609.2006.00739.x","volume":"77","author":"G Birgeg\u00e5rd","year":"2006","unstructured":"Birgeg\u00e5rd G, Gasc\u00f3n P, Ludwig H: Evaluation of anaemia in patients with multiple myeloma and lymphoma: findings of the European CANCER ANAEMIA SURVEY. Eur J Haematol. 2006, 77: 378-386.","journal-title":"Eur J Haematol"},{"key":"4717_CR24","doi-asserted-by":"publisher","first-page":"3724","DOI":"10.1182\/blood-2010-05-282632","volume":"116","author":"M Sant","year":"2010","unstructured":"Sant M, Allemani C, Tereanu C, De Angelis R, Capocaccia R, Visser O, Marcos-Gragera R, Maynadi\u00e9 M, Simonetti A, Lutz JM, Berrino F: Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010, 116: 3724-3734.","journal-title":"Blood"},{"key":"4717_CR25","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1093\/annonc\/mdl498","volume":"18","author":"J Ferlay","year":"2007","unstructured":"Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P: Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol. 2007, 18: 581-592.","journal-title":"Ann Oncol"},{"issue":"Suppl. 5","key":"4717_CR26","doi-asserted-by":"publisher","first-page":"v244","DOI":"10.1093\/annonc\/mdq202","volume":"21","author":"D Schrijvers","year":"2010","unstructured":"Schrijvers D, De Samblanx H, Roila F: Erythropoiesis-stimulating agents in the treatment of anaemia in cancer patients: ESMO Clinical Practice Guidelines for use. Ann Oncol. 2010, 21 (Suppl. 5): v244-v247.","journal-title":"Ann Oncol"},{"issue":"Suppl. 4","key":"4717_CR27","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.6004\/jnccn.2011.0136","volume":"9","author":"AD Zelenetz","year":"2011","unstructured":"Zelenetz AD, Ahmed I, Braud EL, Cross JD, Davenport-Ennis N, Dickinson BD, Goldberg SE, Gottlieb S, Johnson PE, Lyman GH, Markus R, Matulonis UA, Reinke D, Li EC, DeMartino J, Larsen JK, Hoffman JM: NCCN Biosimilars white paper: regulatory, scientific, and patient safety perspectives. J Natl Compr Canc Netw. 2011, 9 (Suppl. 4): S1-S22.","journal-title":"J Natl Compr Canc Netw"}],"updated-by":[{"DOI":"10.1186\/1471-2407-14-720","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2014,9,26]],"date-time":"2014-09-26T00:00:00Z","timestamp":1411689600000}}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-14-503.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-14-503\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-14-503","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,10]],"date-time":"2022-04-10T14:58:21Z","timestamp":1649602701000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-14-503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,10]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["4717"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-14-503","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,10]]},"article-number":"503"}}